Patients with small cell (oat cell) carcinoma of the lung may be separated into prognostic groups based on clinical and laboratory findings.
Parameters:
(1) disease extent (DE, localized vs extensive disease)
(2) if localized, then its stage (LDS, involvement of mediastinum, supraclavicular lymph nodes or pleural space)
(3) serum LDH
(4) white blood cell count (WBCC)
(5) sex (male or female)
(6) liver metastases (LM)
(7) ECOG performance status (PS)
(8) serum alkaline phosphatase (AP)
|
DE |
LDS |
LDH |
WBCC |
Sex |
LM |
PS |
AP |
Stage |
|
LD |
1 |
|
|
|
|
|
|
A1 |
|
LD |
2 |
N |
<= 10 |
F |
|
|
|
A2 |
|
LD |
2 |
N |
<= 10 |
M |
|
|
|
B1 |
|
LD |
2 |
N |
> 10 |
|
|
|
|
B2 |
|
LD |
2 |
E |
|
|
|
|
|
C1 |
|
ED |
|
|
|
F |
N |
0-1 |
|
B3 |
|
ED |
|
|
|
F |
Y |
0-1 |
|
C2 |
|
ED |
|
|
|
M |
|
0-1 |
|
C3 |
|
ED |
|
|
|
|
|
2-3 |
N |
C4 |
|
ED |
|
|
|
|
|
2-3 |
E |
D |
where:
• DE = disease extent; LD = localized disease (confined to the hemithorax, including supraclavicular nodes); ED = extensive disease, indicating distant metastases
• LDS = LD stage with mediastinal involvement; LDS 1 = mediastinum not involved, no involvement of ipsilateral supraclavicular lymph nodes, and no malignant pleural effusion; LDS 2 = mediastinum involved, ipsilateral supraclavicular lymph nodes involved, and/or malignant pleural effusion present
• PS = ECOG performance score (from 0 to 4, where 0 is asymptomatic, 1 is symptomatic but ambulatory, 2 is symptomatic and bedridden less than half the day, 3 is symptomatic and bedridden more than half the day but not totally bedridden, 4 is completely bedridden requiring assistance in activities of daily living
• N = normal, E = elevated
Interpretation
|
Group |
percent with 2 year survival |
percent with 5 year survival |
|
A |
24.8% |
17.6% |
|
B |
13.9% |
4.7% |
|
C |
3% |
0.8% |
|
D |
0% |
0% |
Specialty: Hematology Oncology, Surgery, general, Pulmonology
ICD-10: ,
